Search results

Using our content internationally. Includes information on fees and licensing agreements for both AI and non AI requests.

Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.

Learn more about what NICE content is available for reuse by checking our information asset register.

Learn about situations where you cannot use NICE content.

Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.

RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.

How we collect and use your personal information, and your rights under data protection legislation.

Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

Find out more about the NICE technology appraisal advisory committee B members and their registered interests

Study NICE and LSE's Executive MSc Healthcare Decision-Making

We offer a dedicated training opportunity to achieve competency in curriculum outcome KA7.5.

Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.

Our recommendations on the use of highly specialised technologies are made by an independent advisory committee

Read the biographies of our medical technologies advisory committee members.